Results 71 to 80 of about 8,953 (160)

DIPG-16. DELAYED RT IN SELECT PATIENTS WITH DIPG [PDF]

Neuro-Oncology, 2018
Kevin De Braganca, Viviana Benitez, Stephen Gilheeney, Matthias Karajannis, Yasmin Khakoo, Kim Kramer, Suzanne Wolden   +6 more
openaire   +1 more source

DIPG-60. OPERATIVE PERFORMANCE OF RAPNO DIPG CRITERIA FOR IMAGING REVIEW- A STUDY FROM THE INTERNATIONAL DIPG/DMG REGISTRY (IDIPGR)

Neuro-Oncology
Abstract BACKGROUND The Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group for diffuse intrinsic pontine glioma (DIPG) recently published its recommendations. Response criteria incorporate radiologic findings, neurologic status, and use of concurrent steroids and antiangiogenic ...
Gorsi, Hamza S, Guryildirim, Melike, Kuwabara, Michael, Dhatt, Jovan, Hoffman, Lindsey M, Cohen, Kenneth J   +5 more
openaire   +1 more source

Convection enhanced delivery of panobinostat (LBH589)-loaded pluronic nano-micelles prolongs survival in the F98 rat glioma model [PDF]

, 2017
BACKGROUND: The pan-histone deacetylase inhibitor panobinostat is a potential therapy for malignant glioma, but it is water insoluble and does not cross the blood–brain barrier when administered systemically. In this article, we describe the in vitro and
Asby, D. J., Barua, N. U., Bienemann, A. S., Butts, C. P., Collins, A. M., Gill, S. S., Haynes, H. R., Killick-Cole, C. L., Singleton, W. G., Wyatt, M. J.   +9 more
core   +2 more sources

DIPG-75. INTERSECTION OF EPIGENETICS AND IMMUNITY IN DIPG [PDF]

Neuro-Oncology, 2018
Allison Martin, Robert Bell, Charles Eberhart, Eric Raabe, Michael Koldobskiy   +4 more
openaire   +1 more source

DIPG-49. STAT3 AS A THERAPEUTIC TARGET IN DIPG [PDF]

Neuro-Oncology, 2018
Nagore G Olaciregui, Diana Carvalho, Alan Mackay, Guillem Pascual-Pasto, Matthew Clarke, Valeria Molinari, Elisa Izquierdo, Jordan Goncalves, Yann Courbebaisse, Andres Morales La Madrid, Mariona Suñol, Ofelia Cruz, Jaume Mora, Chris Jones, Angel M Carcaboso   +14 more
openaire   +1 more source

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy. [PDF]

, 2018
Malignant gliomas carry a dismal prognosis. Conventional treatment using chemo- and radiotherapy has limited efficacy with adverse events. Therapy with genetically engineered T-cells, such as chimeric antigen receptor (CAR) T-cells, may represent a ...
Almeida, Neil D, Chuntova, Pavlina, Downey, Kira M, Hegde, Bindu, Okada, Hideho   +4 more
core  

Gender-Specific Differences between the Concentrations of Nonvolatile (R)/(S)-3-Methyl-3-Sulfanylhexan-1-Ol and (R)/(S)-3-Hydroxy-3-Methyl-Hexanoic Acid Odor Precursors in Axillary Secretions [PDF]

, 2017
The volatile fatty acid, (R)/(S)-3-hydroxy-3-methylhexanoic acid ((R)/(S)-HMHA), and the human specific volatile thiol, (R)/(S)-3-methyl-3-sulfanylhexan-1-ol ((R)/(S)-MSH), were recently identified as major components of human sweat malodor.
Beccucci, Sabine, Borchard, Gerrit, Niclass, Yvan, Raviot-Derrien, Sophie, Starkenmann, Christian, Troccaz, Myriam, Vuilleumier, Christine   +6 more
core  

Modeling DIPG in the mouse brainstem [PDF]

Neuro-Oncology, 2020
Robert, Siddaway, Cynthia, Hawkins
openaire   +2 more sources

DIPG-10. MULTIMODAL IMMUNOTHERAPY AS PART OF MULTIMODAL TREATMENT FOR DIPG [PDF]

Neuro-Oncology, 2017
Stefaan Van Gool, Maria Lulei, Volker Schirrmacher, Wilfried Stuecker   +3 more
openaire   +1 more source

DIPG-26. NON-INFLAMMATORY EFFECT OF DIPG ON TUMOR-ASSOCIATED MICROGLIA [PDF]

Neuro-Oncology, 2017
Grant Lin, Michelle Monje
openaire   +1 more source